SG11201901525XA - Muscarinic m1 receptor positive allosteric modulators - Google Patents
Muscarinic m1 receptor positive allosteric modulatorsInfo
- Publication number
- SG11201901525XA SG11201901525XA SG11201901525XA SG11201901525XA SG11201901525XA SG 11201901525X A SG11201901525X A SG 11201901525XA SG 11201901525X A SG11201901525X A SG 11201901525XA SG 11201901525X A SG11201901525X A SG 11201901525XA SG 11201901525X A SG11201901525X A SG 11201901525XA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- hyderabad
- serene
- chambers
- life sciences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Arrangement And Driving Of Transmission Devices (AREA)
- Electrophonic Musical Instruments (AREA)
- Liquid Crystal Display Device Control (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
International Patent Classification: CO7D 471/04 (2006.01) A61K 31/4375 (2006.01) A61K 31/436 (2006.01) C07D 491/04 (2006.01) A61K 31/4353 (2006.01) C07D 498/04 (2006.01) A61K 31/437 (2006.01) A61P 25/00 (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) REVISED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIPO I PCT 11111111111101101010111110111101011 110E 0111001110101E0M1110# (10) International Publication Number WO 2018/042362 A9 PCT/IB2017/055238 (22) International Filing Date: 31 August 2017 (31.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201641030062 02 September 2016 (02.09.2016) IN 201741013343 13 April 2017 (13.04.2017) IN (71) Applicant: SUVEN LIFE SCIENCES LIMITED [IN/IN]; Serene Chambers, Road - 5, Avenue — 7, Banjara Hills, Hyderabad,Telangana 500 034 (IN). (72) Inventors: NIROGI, Ramakrishna; Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana 500034 (IN). SHINDE, Anil Karbhari; Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana 500034 (IN). MOHAMMED, Abdul Rasheed; Suven Life Sciences Limited, Serene Chambers, Road-5, Av- enue — 7, Banjara Hills, Hyderabad,Telangana 500034 (IN). BADANGE, Rajesh Kumar; Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana 500034 (IN). JAYARAJAN, Pradeep; Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- gana 500034 (IN). BHYRAPUNENI, Gopinadh; Suven Life Sciences Limited, Serene Chambers, Road-5, Av- enue — 7, Banjara Hills, Hyderabad,Telangana 500034 (IN). JASTI, Venkateswarlu; Suven Life Sciences Limit- ed, Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana 500034 (IN). (74) Agent: KAPOOR, Divya et al.; Central Square, Suite-328, Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu Rao (off Rani Jhansi Road), Delhi 110006 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the revised international search report: 03 May 2018 (03.05.2018) (54) Title: MUSCARINIC Ml RECEPTOR POSITIVE ALLOSTERIC MODULATORS W O 20 18/04236 2 A9 (I) (57) : The present invention relates to compounds of formu- la (I), or their isotopic forms, stereoisomers, tautomers or pharmaceu- tically acceptable salt (s) thereof as muscarinic Ml receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound for- mula (I). [Continued on next page] WO 2018/042362 A9 MIDEDIMOM0101011MOIER1001111111111111111101111111011111110B10# (15) Information about Correction: see Notice of 03 May 2018 (03.05.2018)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641030062 | 2016-09-02 | ||
IN201741013343 | 2017-04-13 | ||
PCT/IB2017/055238 WO2018042362A1 (en) | 2016-09-02 | 2017-08-31 | Muscarinic m1 receptor positive allosteric modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901525XA true SG11201901525XA (en) | 2019-03-28 |
Family
ID=59982423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901525XA SG11201901525XA (en) | 2016-09-02 | 2017-08-31 | Muscarinic m1 receptor positive allosteric modulators |
Country Status (23)
Country | Link |
---|---|
US (1) | US11040026B2 (en) |
EP (1) | EP3507289B1 (en) |
JP (1) | JP6629486B2 (en) |
KR (1) | KR102017786B1 (en) |
CN (1) | CN109952302B (en) |
AU (1) | AU2017319609B2 (en) |
BR (1) | BR112019003932A2 (en) |
CA (1) | CA3034775C (en) |
CY (1) | CY1123479T1 (en) |
ES (1) | ES2824495T3 (en) |
HR (1) | HRP20201539T1 (en) |
HU (1) | HUE053586T2 (en) |
IL (1) | IL264951B (en) |
LT (1) | LT3507289T (en) |
MA (1) | MA46101B1 (en) |
MD (1) | MD3507289T2 (en) |
MX (1) | MX2019002180A (en) |
PL (1) | PL3507289T3 (en) |
PT (1) | PT3507289T (en) |
RS (1) | RS60875B1 (en) |
SG (1) | SG11201901525XA (en) |
SI (1) | SI3507289T1 (en) |
WO (1) | WO2018042362A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019504901A (en) | 2016-02-16 | 2019-02-21 | ヴァンダービルト ユニバーシティー | Positive allosteric modulator of muscarinic acetylcholine receptor M1 |
WO2018063552A1 (en) | 2016-09-30 | 2018-04-05 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
FI3643718T3 (en) | 2017-06-20 | 2023-11-01 | Takeda Pharmaceuticals Co | Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor. |
CN110709401B (en) * | 2017-06-20 | 2023-06-13 | 武田药品工业株式会社 | Heterocyclic compounds |
MA50464A (en) * | 2017-10-27 | 2021-06-02 | Suven Life Sciences Ltd | POLYCYCLIC AMIDES USED AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR |
HUE057970T2 (en) | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopyrazine diol compounds as pi3k-y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
EP3858838A4 (en) | 2018-09-28 | 2022-06-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2020067457A1 (en) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | Condensed-cyclic compound |
EP3858828A4 (en) * | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN113166160B (en) * | 2018-10-17 | 2023-12-19 | 苏文生命科学有限公司 | Pyrrolopyridazine derivatives as modulators of the positive allosteric of the muscarinic M1 receptor |
AU2020358000A1 (en) | 2019-10-04 | 2022-04-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009155052A1 (en) | 2008-05-28 | 2009-12-23 | Wyeth | 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
GEP201606506B (en) * | 2009-12-17 | 2016-07-11 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
US8883850B2 (en) | 2010-05-28 | 2014-11-11 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide M1 receptor positive allosteric modulators |
US8815902B2 (en) * | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
WO2012158474A1 (en) * | 2011-05-17 | 2012-11-22 | Merck Sharp & Dohme Corp. | N-linked quinolineamide m1 receptor positive allosteric modulators |
AR088082A1 (en) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | ANDROGEN RECEIVER SELECTIVE MODULATORS |
TW201512197A (en) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | Pyrrolopyridine or pyrazolopyridine derivatives |
EP3097094B1 (en) | 2014-01-22 | 2020-01-15 | F.Hoffmann-La Roche Ag | Fluoro-naphthyl derivatives |
EP3156397B1 (en) * | 2014-06-13 | 2019-08-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
WO2016009297A1 (en) * | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
JP2019504901A (en) * | 2016-02-16 | 2019-02-21 | ヴァンダービルト ユニバーシティー | Positive allosteric modulator of muscarinic acetylcholine receptor M1 |
-
2017
- 2017-08-31 PL PL17777380T patent/PL3507289T3/en unknown
- 2017-08-31 CA CA3034775A patent/CA3034775C/en active Active
- 2017-08-31 RS RS20201170A patent/RS60875B1/en unknown
- 2017-08-31 MD MDE20190759T patent/MD3507289T2/en unknown
- 2017-08-31 MX MX2019002180A patent/MX2019002180A/en unknown
- 2017-08-31 CN CN201780063068.6A patent/CN109952302B/en active Active
- 2017-08-31 SG SG11201901525XA patent/SG11201901525XA/en unknown
- 2017-08-31 EP EP17777380.1A patent/EP3507289B1/en active Active
- 2017-08-31 MA MA46101A patent/MA46101B1/en unknown
- 2017-08-31 PT PT177773801T patent/PT3507289T/en unknown
- 2017-08-31 AU AU2017319609A patent/AU2017319609B2/en active Active
- 2017-08-31 WO PCT/IB2017/055238 patent/WO2018042362A1/en active Search and Examination
- 2017-08-31 US US16/327,742 patent/US11040026B2/en active Active
- 2017-08-31 BR BR112019003932-5A patent/BR112019003932A2/en active Search and Examination
- 2017-08-31 LT LTEP17777380.1T patent/LT3507289T/en unknown
- 2017-08-31 HU HUE17777380A patent/HUE053586T2/en unknown
- 2017-08-31 JP JP2019510925A patent/JP6629486B2/en active Active
- 2017-08-31 SI SI201730419T patent/SI3507289T1/en unknown
- 2017-08-31 KR KR1020197008723A patent/KR102017786B1/en active IP Right Grant
- 2017-08-31 ES ES17777380T patent/ES2824495T3/en active Active
-
2019
- 2019-02-21 IL IL264951A patent/IL264951B/en unknown
-
2020
- 2020-09-28 HR HRP20201539TT patent/HRP20201539T1/en unknown
- 2020-10-08 CY CY20201100944T patent/CY1123479T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102017786B1 (en) | 2019-09-03 |
BR112019003932A2 (en) | 2019-05-21 |
EP3507289A1 (en) | 2019-07-10 |
ES2824495T3 (en) | 2021-05-12 |
SI3507289T1 (en) | 2020-11-30 |
CA3034775A1 (en) | 2018-03-08 |
CN109952302A (en) | 2019-06-28 |
AU2017319609B2 (en) | 2019-11-14 |
LT3507289T (en) | 2020-10-12 |
HRP20201539T1 (en) | 2021-02-05 |
US20190343812A1 (en) | 2019-11-14 |
AU2017319609A1 (en) | 2019-03-14 |
WO2018042362A1 (en) | 2018-03-08 |
MX2019002180A (en) | 2019-08-16 |
KR20190038666A (en) | 2019-04-08 |
PL3507289T3 (en) | 2021-01-25 |
MA46101A (en) | 2019-07-10 |
MD3507289T2 (en) | 2020-11-30 |
IL264951B (en) | 2021-09-30 |
CA3034775C (en) | 2020-07-14 |
RS60875B1 (en) | 2020-11-30 |
WO2018042362A9 (en) | 2018-05-03 |
CN109952302B (en) | 2020-11-24 |
MA46101B1 (en) | 2020-10-28 |
NZ751569A (en) | 2020-11-27 |
EP3507289B1 (en) | 2020-07-15 |
US11040026B2 (en) | 2021-06-22 |
HUE053586T2 (en) | 2021-07-28 |
JP2019526566A (en) | 2019-09-19 |
CY1123479T1 (en) | 2022-03-24 |
PT3507289T (en) | 2020-10-01 |
JP6629486B2 (en) | 2020-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201900634VA (en) | Chimeric antigen receptor | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201906163TA (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus | |
SG11201902531QA (en) | Liquid pharmaceutical composition | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810516UA (en) | Combinations comprising histone deacetylase inhibitors | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers |